Globus Medical Announces $500M Share Buyback Program

Globus Medical ( (GMED) ) has issued an announcement.

On May 15, 2025, Globus Medical announced a $500 million share repurchase program authorized by its Board of Directors, reflecting confidence in the company’s intrinsic value and commitment to long-term shareholder value. The program, aimed at addressing recent share price volatility, will be funded through cash reserves and executed based on market conditions and strategic priorities, with no set time limit.

The most recent analyst rating on (GMED) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Globus Medical stock, see the GMED Stock Forecast page.

Spark’s Take on GMED Stock

According to Spark, TipRanks’ AI Analyst, GMED is a Neutral.

Globus Medical’s overall stock score reflects a balance of strong financial performance and cash flow with technical weakness and high valuation concerns. The acquisition of Nevro is a promising strategic move, but current operational challenges and a premium valuation suggest a cautious approach in the near term.

To see Spark’s full report on GMED stock, click here.

More about Globus Medical

Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs and advancing care in spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies.

Average Trading Volume: 1,487,077

Technical Sentiment Signal: Sell

Current Market Cap: $7.89B

See more data about GMED stock on TipRanks’ Stock Analysis page.